Slide 1: Commercialising AI-driven solutions to objectively screen for mental health conditions
For personal use only Commercialising AI-driven solutions to objectively screen for mental health conditions Investor presentation – May 2024 (ASX: TRI) This presentation has been authorised for release by the Board of TrivarX Limited
Slide 2: Forward looking statements
Forward looking statements For personal use only The purpose of the presentation is to provide an update of the business of TrivarX Limited (ASX: TRI). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Ac
Slide 3: Corporate overview
Corporate overview For personal use only Corporate snapshot Share price and volume** (May 2023– May 2024) ASX code: TRI Shares on issue: ~409.6m Market capitalisation (at $0.027 per share): ~A$12.3m (as at 21 May 2024) Options on issue: ~158.3m Debt: Nil Board and management Non-Executive Chairman M
Slide 4: Company overview
Company overview A US-based company pioneering the use of AI to aid in the early detection of mental health conditions For personal use only Commercialising AI-driven, scientifically-backed diagnostic tools to objectively screen and assist in the diagnosis of mental health conditions MEB-001 utilise
Slide 5: The US mental health epidemic
The US mental health epidemic Exploring the robust relationship between sleep and mental health in the US For personal use only 1 in 5 American adults (~57m people) experience a mental illness 1 in 25 US adults live with a serious mental health condition including major depression, bipolar and schiz
Slide 6: A scientifically backed approach
A scientifically backed approach Underpinned by leading management, extensive experience and industry validation For personal use only Extensive industry validation: Leading Scientific expertise: - Since the early 2000s, TRI’s dedicated scientific personnel have built Archie Defillo M.D. – Chief Med
Slide 7: Product overview
Product overview Interrelated product suite with significant commercialisation and scale up potential For personal use only Stager MEB-001 - AI-based software that provides researchers with unique - An innovative machine learning and AI-backed algorithm to HR and HRV metrics combined with hypnodensi
Slide 8: Stager – Uptake and ongoing commercialisation
Stager – Uptake and ongoing commercialisation Stager solution unlocks potential to establish a strong in-market presence while strengthening MEB-001 For personal use only - Data collection from partnerships and deployments further strengthens MEB-001 by further informing company’s core algorithms -
Slide 9: MEB-001 – redefining sleep and depression
MEB-001 – redefining sleep and depression MEB-001 has the potential to become the standard depression symptom screening tool within US Health For personal use only Systems Clinical Regulatory - TrivarX’s proprietary algorithm is being developed as a tool to be used to screen and aid in the diagnosis
Slide 10: MEB-001 – Promising Phase 1 trial results
MEB-001 – Promising Phase 1 trial results - Sleep Signal Analysis of Depression Burden (SAMDE) Study Phase 1 clinical trial completed in July 2023 For personal use only - Aim of SAMDE Phase 1 trial was to detect the likelihood cMDE in individuals referred to sleep clinics for polysomnography (PSG) a
Slide 11: Phase 2 SAMDE trial and interim results
Phase 2 SAMDE trial and interim results - Phase 2 trial aims to detect likelihood of a cMDE using Clinician Reporting Outcomes (CRO) assessment in individuals referred to a sleep For personal use only clinical for PSG assessment using TRI’s algorithm - Phase 2 to test up to 400 participants from 15
Slide 12: Commercial model and go to market strategy
Commercial model and go to market strategy Potential for rapid adoption of MEB-001 through strategic partnerships with US sleep labs For personal use only Commercial model Go to market strategy - Currently, there are ~980,000 sleep tests done in the US per annum - Leverage existing partnerships with
Slide 13: Multiple near-term value catalysts
Multiple near-term value catalysts For personal use only Finalisation of comprehensive Phase 2 SAMDE study to validate data – study which has over 300 patients enrolled to-date and is advancing in accordance with its stated completion timeline (June quarter 2024). Ongoing dialogue with the US Food &
Slide 14: Contact
Contact Contact For personal use only TrivarX Limited (ASX: TRI) E: Investors@trivarx.com A: 647 Beaufort Street, Mt Lawley, WA 6050 Kai Sun – Chief Operating Officer: T: +61 433 549 602 E: Kai.sun@trivarx.com Henry Jordan – Six Degrees Investor Relations T: +61 431 271 538 E: Henry.Jordan@sdir.com.
Slide 15: Appendix 1: Intellectual Property and patents
Appendix 1: Intellectual Property and patents Four patents granted and currently active For personal use only 1 2 US Pat. No. 10,912,508 - Issued 09 Feb 2021. US Pat. No. 10,638,965 - Issued 05 May 2020. Method and system for assessing mental state Method and system for monitoring stress conditions.
Slide 16: Appendix 2: Clinical research and technology
Appendix 2: Clinical research and technology Supervised Artificial Intelligence For personal use only Clinical Data has been taken from 400+ subjects to date: Clinical Study SLEEP SADB SAMDE PI SAMDE PII Validation Status Complete Complete Complete Underway Planned - Prospective data collection – re